New composition of the management board of BioPorto A/S
November 19, 2021 10:52 ET
|
BioPorto A/S
November 19, 2021Announcement no. 22New composition of the management board of BioPorto A/S With reference to announcement nos. 16 and 17 regarding the appointment of Anthony Pare and Neil A....
BioPorto Announces Q3 2021 Report
November 17, 2021 02:53 ET
|
BioPorto A/S
November 17, 2021Announcement no. 21Q3 2021 Report Highlights Revenue growth driven by antibodies and RUO sales of The NGAL Test In the first nine months of 2021, BioPorto’s revenue...
BioPorto A/S - Extraordinary General Meeting, New Board Member
November 15, 2021 09:55 ET
|
BioPorto A/S
November 15, 2021Announcement no. 20 BioPorto A/S - Extraordinary General Meeting, New Board Member Today, BioPorto A/S held an Extraordinary General Meeting where Peter Mørch Eriksen was elected...
Update on Patient Enrollment for Pivotal Study of NGAL in Pediatrics
November 03, 2021 03:44 ET
|
BioPorto A/S
November 3, 2021Announcement no. 19 Update on Patient Enrollment for Pivotal Study of NGAL in Pediatrics COVID-19 has continued to impact hospital operations and BioPorto’s enrollment of pediatric...
Notice Convening the Extraordinary General Meeting
October 22, 2021 03:01 ET
|
BioPorto A/S
October 22, 2021 Announcement no. 18 NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING With reference to company announcement no. 16, the Board of Directors hereby convenes an...
BioPorto A/S appoints new Chief Financial Officer
October 20, 2021 02:24 ET
|
BioPorto A/S
October 20, 2021Announcement no. 17 BioPorto A/S appoints new Chief Financial Officer BioPorto A/S (“BioPorto”) today announces the appointment of Neil A. Goldman, CPA as its new Executive Vice...
BioPorto A/S appoints new Chief Executive Officer and announces changes to the Board of Directors
October 20, 2021 02:16 ET
|
BioPorto A/S
October 20, 2021Announcement no. 16 BioPorto A/S appoints new Chief Executive Officer and announces changes to the Board of Directors BioPorto A/S (“BioPorto”) has announced the appointment of...
BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results
August 31, 2021 04:10 ET
|
BioPorto A/S
August 31, 2021Announcement no. 15 BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results BioPorto A/S (BioPorto) has successfully...
BioPorto Announces Q2 2021 Report
August 18, 2021 02:59 ET
|
BioPorto A/S
August 18, 2021Announcement no. 14Q2 2021 Report Highlights Solid revenue growth in the first half of 2021 In the first half of 2021, BioPorto’s revenue grew by 20% measured in USD and...
Pipeline Update Regarding COVID-19 test
June 29, 2021 06:32 ET
|
BioPorto A/S
June 29, 2021Announcement no. 13 Pipeline Update Regarding COVID-19 test BioPorto A/S (BioPorto) is currently developing a point-of-care test for SARS-CoV-2 on the proprietary gRAD platform...